MT Newswires
Piper Sandler Adjusts Price Target on Amgen to $432 From $381, Maintains Overweight Rating
📊
AI Sentiment
Positive
7/10
- Home
- AMGN
AMGN
Amgen Inc.
as of 02-18-2026 3:36pm EST
$377.82
+$4.45
+1.19%
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | US |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 197.4B | IPO Year: | 1999 |
| Target Price: | $341.69 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Hold | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 14.23 | EPS Growth: | 88.23 |
| 52 Week Low/High: | $265.66 - $385.12 | Next Earning Date: | 05-05-2026 |
| Revenue: | $25,424,000,000 | Revenue Growth: | 8.83% |
| Revenue Growth (this year): | 4.88% | Revenue Growth (next year): | 2.58% |
| P/E Ratio: | 26.63 | Index: | |
| Free Cash Flow: | 8.1B | FCF Growth: | -22.07% |
AI-Powered AMGN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.23%
74.23%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
MT Newswires
Rothschild & Co Redburn Adjusts Price Target on Amgen to $200 From $180, Maintains Sell Rating
📊
AI Sentiment
Positive
7/10
PR Newswire
MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERSHIP TEAM
📈
AI Sentiment
Highly Positive
8/10
Investor's Business Daily
Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk
📉
AI Sentiment
Negative
2/10
Simply Wall St.
Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?
📊
AI Sentiment
Positive
7/10
MarketBeat
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
📊
AI Sentiment
Positive
7/10
Insider Monkey
Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
📈
AI Sentiment
Highly Positive
9/10
Compare AMGN vs Leading Stocks
See how AMGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.